MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways

Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therap...

Descripción completa

Detalles Bibliográficos
Autores: Majem, Blanca, Parrilla, Alfonso, Jiménez, Carlos, Marin, Andrea, Suárez, Leticia, Castellví, Josep, Tamayo, Gabriel, Moreno, Gema, Ponce i Sebastià, Jordi, Matias-Guiu, Xavier, 1958-, Alameda, Francesc, Romero, Ignacio, Sánchez, José Luis, Pérez Benavente, Asunción, Moran, Sebastian, Esteller, Manel, 1968-, Reventós Puigjaner, Jaume, Rigau, Marina, Gil Moreno, Antonio, Segura, Miguel F., Santamaria Margalef, Anna
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/147966
Acceso en línea:https://hdl.handle.net/2445/147966
Access Level:acceso abierto
Palabra clave:Apoptosi
Epigenètica
Micro RNAs
Càncer d'ovari
Apoptosis
Epigenetics
MicroRNAs
Ovarian cancer
id ES_5efbefebcf00812f63606f3fdbad2a95
oai_identifier_str oai:diposit.ub.edu:2445/147966
network_acronym_str ES
network_name_str España
repository_id_str
spelling MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathwaysMajem, BlancaParrilla, AlfonsoJiménez, CarlosMarin, AndreaSuárez, LeticiaCastellví, JosepTamayo, GabrielMoreno, GemaPonce i Sebastià, JordiMatias-Guiu, Xavier, 1958-Alameda, FrancescRomero, IgnacioSánchez, José LuisPérez Benavente, AsunciónMoran, SebastianEsteller, Manel, 1968-Reventós Puigjaner, JaumeRigau, MarinaGil Moreno, AntonioSegura, Miguel F.Santamaria Margalef, AnnaApoptosiEpigenèticaMicro RNAsCàncer d'ovariApoptosisEpigeneticsMicroRNAsOvarian cancerOvarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.National Academy of Sciences2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/147966Articles publicats en revistes (Ciències Clíniques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1038/s41388-019-0860-0Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 38, p. 6035-6050https://doi.org/10.1038/s41388-019-0860-0(c) Majem, Blanca et al., 2019info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1479662026-05-27T06:46:51Z
dc.title.none.fl_str_mv MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
title MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
spellingShingle MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
Majem, Blanca
Apoptosi
Epigenètica
Micro RNAs
Càncer d'ovari
Apoptosis
Epigenetics
MicroRNAs
Ovarian cancer
title_short MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
title_full MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
title_fullStr MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
title_full_unstemmed MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
title_sort MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
dc.creator.none.fl_str_mv Majem, Blanca
Parrilla, Alfonso
Jiménez, Carlos
Marin, Andrea
Suárez, Leticia
Castellví, Josep
Tamayo, Gabriel
Moreno, Gema
Ponce i Sebastià, Jordi
Matias-Guiu, Xavier, 1958-
Alameda, Francesc
Romero, Ignacio
Sánchez, José Luis
Pérez Benavente, Asunción
Moran, Sebastian
Esteller, Manel, 1968-
Reventós Puigjaner, Jaume
Rigau, Marina
Gil Moreno, Antonio
Segura, Miguel F.
Santamaria Margalef, Anna
author Majem, Blanca
author_facet Majem, Blanca
Parrilla, Alfonso
Jiménez, Carlos
Marin, Andrea
Suárez, Leticia
Castellví, Josep
Tamayo, Gabriel
Moreno, Gema
Ponce i Sebastià, Jordi
Matias-Guiu, Xavier, 1958-
Alameda, Francesc
Romero, Ignacio
Sánchez, José Luis
Pérez Benavente, Asunción
Moran, Sebastian
Esteller, Manel, 1968-
Reventós Puigjaner, Jaume
Rigau, Marina
Gil Moreno, Antonio
Segura, Miguel F.
Santamaria Margalef, Anna
author_role author
author2 Parrilla, Alfonso
Jiménez, Carlos
Marin, Andrea
Suárez, Leticia
Castellví, Josep
Tamayo, Gabriel
Moreno, Gema
Ponce i Sebastià, Jordi
Matias-Guiu, Xavier, 1958-
Alameda, Francesc
Romero, Ignacio
Sánchez, José Luis
Pérez Benavente, Asunción
Moran, Sebastian
Esteller, Manel, 1968-
Reventós Puigjaner, Jaume
Rigau, Marina
Gil Moreno, Antonio
Segura, Miguel F.
Santamaria Margalef, Anna
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Apoptosi
Epigenètica
Micro RNAs
Càncer d'ovari
Apoptosis
Epigenetics
MicroRNAs
Ovarian cancer
topic Apoptosi
Epigenètica
Micro RNAs
Càncer d'ovari
Apoptosis
Epigenetics
MicroRNAs
Ovarian cancer
description Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/147966
url https://hdl.handle.net/2445/147966
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41388-019-0860-0
Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 38, p. 6035-6050
https://doi.org/10.1038/s41388-019-0860-0
dc.rights.none.fl_str_mv (c) Majem, Blanca et al., 2019
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Majem, Blanca et al., 2019
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv National Academy of Sciences
publisher.none.fl_str_mv National Academy of Sciences
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409170733662208
score 15,300719